DRUG · Unmapped registry intervention
SOC Chemotherapy
Find medicine records ·
Find other trials using this name
Clinical trial
Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
NCT05846789
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Unmapped registry intervention
Tocilizumab/Tocilizumab Biosimilar
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedToci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Metastatic Breast Cancerunresolved
Triple Negative Breast Cancerunresolved
Estrogen-receptor-low Breast Cancerunresolved
ER Positive, HER2 Negative Breast Cancerunresolved
Interventions
Sponsors & collaborators
Kathy Millerlead sponsor
Genentech, Inc.collaborator
Breast Cancer Research Foundationcollaborator
Susan G. Komen Breast Cancer Foundationcollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05846789 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.